![MONALEESA-2 subgroup analysis of locally assessed PFS. Data cut-off, 2... | Download Scientific Diagram MONALEESA-2 subgroup analysis of locally assessed PFS. Data cut-off, 2... | Download Scientific Diagram](https://www.researchgate.net/publication/328390587/figure/fig1/AS:683497253515267@1539969852276/MONALEESA-2-subgroup-analysis-of-locally-assessed-PFS-Data-cut-off-2-January-2017_Q640.jpg)
MONALEESA-2 subgroup analysis of locally assessed PFS. Data cut-off, 2... | Download Scientific Diagram
![Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study - Clinical Breast Cancer Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study - Clinical Breast Cancer](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/465b8c52-0658-4e87-8572-4acc3bb8b28c/gr1.jpg)
Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study - Clinical Breast Cancer
![MONALEESA-3 OS Update - Capsule Summary Slidesets - Breast Cancer and Gynecologic Cancers - 2021 ASCO Virtual Annual Meeting - Oncology - Clinical Care Options MONALEESA-3 OS Update - Capsule Summary Slidesets - Breast Cancer and Gynecologic Cancers - 2021 ASCO Virtual Annual Meeting - Oncology - Clinical Care Options](https://www.clinicaloptions.com/-/media/oncology/conferences/2021/clinical-oncology-2021/breast-and-gyn/cco_clinical_oncology_2021_1001_thumb.png?rev=89822cd459eb49d59820119d7e07cef6&h=200&as=1&hash=A77DFACD1D5A6690ADEF12AB63CB5B642B213E4F)
MONALEESA-3 OS Update - Capsule Summary Slidesets - Breast Cancer and Gynecologic Cancers - 2021 ASCO Virtual Annual Meeting - Oncology - Clinical Care Options
![Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial | Breast Cancer Research | Full Text Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial | Breast Cancer Research | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13058-018-1050-7/MediaObjects/13058_2018_1050_Fig1_HTML.png)
Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial | Breast Cancer Research | Full Text
Novartis Kisqali® reports longest median overall survival in postmenopausal HR+/HER2- metastatic breast cancer patients
![MONALEESA clinical program: a review of ribociclib use in different clinical settings | Future Oncology MONALEESA clinical program: a review of ribociclib use in different clinical settings | Future Oncology](https://www.futuremedicine.com/cms/10.2217/fon-2019-0130/asset/images/medium/figure1.gif)
MONALEESA clinical program: a review of ribociclib use in different clinical settings | Future Oncology
![PDF] Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer | Semantic Scholar PDF] Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/209632dabf2da4cb7603c235e661f27e804de4df/3-Figure1-1.png)
PDF] Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer | Semantic Scholar
![MONALEESA-2: Overall Survival Benefit Demonstrated in HR+ Advanced Breast Cancer with CDK 4/6 Inhibitor - The Medical Xchange MONALEESA-2: Overall Survival Benefit Demonstrated in HR+ Advanced Breast Cancer with CDK 4/6 Inhibitor - The Medical Xchange](https://themedicalxchange.com/wp-content/uploads/2021/09/MXCR-2436_ESMO_2021_Fig_3.png)
MONALEESA-2: Overall Survival Benefit Demonstrated in HR+ Advanced Breast Cancer with CDK 4/6 Inhibitor - The Medical Xchange
![Ribociclib plus letrozole in subgroups of special clinical interest with hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: Subgroup analysis of the phase IIIb CompLEEment-1 trial - The Breast Ribociclib plus letrozole in subgroups of special clinical interest with hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: Subgroup analysis of the phase IIIb CompLEEment-1 trial - The Breast](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/db206bbf-0dbc-4e12-848a-78676843331a/gr1.jpg)
Ribociclib plus letrozole in subgroups of special clinical interest with hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: Subgroup analysis of the phase IIIb CompLEEment-1 trial - The Breast
![MONALEESA-2: Overall Survival Benefit Demonstrated in HR+ Advanced Breast Cancer with CDK 4/6 Inhibitor - The Medical Xchange MONALEESA-2: Overall Survival Benefit Demonstrated in HR+ Advanced Breast Cancer with CDK 4/6 Inhibitor - The Medical Xchange](https://themedicalxchange.com/wp-content/uploads/2021/09/MXCR-2436_ESMO_2021_Fig_1.png)
MONALEESA-2: Overall Survival Benefit Demonstrated in HR+ Advanced Breast Cancer with CDK 4/6 Inhibitor - The Medical Xchange
![Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - ScienceDirect Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0960977620301867-gr2c.jpg)
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - ScienceDirect
![Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial | Breast Cancer Research | Full Text Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial | Breast Cancer Research | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13058-018-1050-7/MediaObjects/13058_2018_1050_Fig2_HTML.png)
Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial | Breast Cancer Research | Full Text
![Dr Sunil Verma on Twitter: "Monaleesa 7 results by @DrDebuTripathy - first line Ribociclib in pre/peri-menopausal HR+ve MBC. Improved PFS (HR 0.55) #SABCS17 https://t.co/rOYQSEEH7C" / Twitter Dr Sunil Verma on Twitter: "Monaleesa 7 results by @DrDebuTripathy - first line Ribociclib in pre/peri-menopausal HR+ve MBC. Improved PFS (HR 0.55) #SABCS17 https://t.co/rOYQSEEH7C" / Twitter](https://pbs.twimg.com/media/DQZYm55VAAAbN9H.jpg:large)
Dr Sunil Verma on Twitter: "Monaleesa 7 results by @DrDebuTripathy - first line Ribociclib in pre/peri-menopausal HR+ve MBC. Improved PFS (HR 0.55) #SABCS17 https://t.co/rOYQSEEH7C" / Twitter
![Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - The Breast Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - The Breast](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/97e331df-3067-446e-b347-644f7056f58b/gr2c_lrg.jpg)
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - The Breast
![Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial - The Lancet Oncology Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/3e711a09-26b3-4b65-9afb-f24759ce759f/gr1.gif)
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial - The Lancet Oncology
Overall survival results from the phase III MONALEESA-2 trial of postmenopausal patients with HR+/HER2- advanced breast cancer
![Safety and impact of dose reductions on efficacy in the randomised MONALEESA -2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer | British Journal of Cancer Safety and impact of dose reductions on efficacy in the randomised MONALEESA -2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer | British Journal of Cancer](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41416-021-01415-9/MediaObjects/41416_2021_1415_Fig1_HTML.png)
Safety and impact of dose reductions on efficacy in the randomised MONALEESA -2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer | British Journal of Cancer
![Frontiers | Endocrine and Targeted Therapy for Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer: Insights to Sequencing Treatment and Overcoming Resistance Based on Clinical Trials Frontiers | Endocrine and Targeted Therapy for Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer: Insights to Sequencing Treatment and Overcoming Resistance Based on Clinical Trials](https://www.frontiersin.org/files/Articles/455698/fonc-09-00510-HTML/image_m/fonc-09-00510-g001.jpg)
Frontiers | Endocrine and Targeted Therapy for Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer: Insights to Sequencing Treatment and Overcoming Resistance Based on Clinical Trials
![CDK4/6 Inhibitors: Game Changers in the Management of Hormone Receptor–Positive Advanced Breast Cancer? CDK4/6 Inhibitors: Game Changers in the Management of Hormone Receptor–Positive Advanced Breast Cancer?](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/9382cd915ab363fe76cf47f96c2afb714bf6b425-756x442.png/1805shahtable1_0.png?fit=crop&auto=format)